The downgrade from a Strong Buy to Market Perform by a reputable analyst firm like Raymond James can lead to a negative perception among investors, potentially causing a short-term decline in the stock's price. This change reflects a significant shift in the firm's outlook on Fusion Pharmaceuticals, likely due to updated analysis or market conditions that could impact the company's future performance.